No Data
Everest Medicines to Drop B Marker From Stock Short Name
EVEREST MED-B: 2024 Annual Report
Is There An Opportunity With Everest Medicines Limited's (HKG:1952) 49% Undervaluation?
EVEREST MED-B (01952): "Dual drivers + annual commercialization profitability" breaks the deadlock, aiming to set a new benchmark in Biopharma.
In recent years, amid the accelerated reform opportunities in the domestic Innovative Drugs market, EVEREST MED-B (01952) has fully accelerated innovation with a "dual-drive" approach, relying on strong independent research and development capabilities in Innovative Drugs and AI pharmaceuticals, supplemented by external authorization and partnership.
EVEREST MED-B (01952): Rules 18A.09 to 18A.11 do not apply.
EVEREST MED-B (01952) issued an announcement in accordance with the Hong Kong Exchange's Listing Rules Section 18...
EVEREST MED-B (01952.HK): The stock name will no longer have the "B" label added.
On April 22, Gelonghui reported that EVEREST MED-B (01952.HK) announced that, in accordance with Rule 18A.12 of the Listing Rules of the Stock Exchange, an application made to the Stock Exchange has been approved, exempting the company from the applicable provisions of Rules 18A.09 to 18A.11 ("Relevant Rules"). Due to the inapplicability of the Relevant Rules, the company's English and Chinese stock names will no longer include the "B" designation. The company will announce the effective date for the removal of the "B" designation at an appropriate time.
Press Release: Everest Medicines Strengthens Management Team With Appointments of Chief Medical Officer and Chief Product Officer
